US 6,627,196 B1
Dosages for treatment with anti-ErbB2 antibodiesGeneral
US 6,627,196 B1
Dosages for treatment with anti-ErbB2 antibodies
Tech Center:
1600 Biotechnology and Organic Chemistry
Examiner:
Anthony C. Caputa
Art Unit:
1642 Immunology, Receptor/Ligands, Cytokines Recombinant Hormones, and Molecular Biology
Agent:
Inventors:
Sharon A. Baughman; Steven Shak
Assignee:
Priority:
08/27/99
Filed:
08/25/00
Granted:
09/30/03
Expiration:
08/25/20
Abstract
The present invention concerns the treatment of disorders characterized by the overexpression of ErbB2. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer overexpressing ErbB2 with anti-ErbB2 antibody.